Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News

News :
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors 
The feature you requested does not exist. However, we suggest the following feature:

KURA ONCOLOGY, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/15/2019 | 08:03am EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 14, 2019, the Board of Directors (the "Board") of Kura Oncology, Inc. (the "Company"), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Diane Parks as a Class III director of the Company, with a term of office expiring at the 2020 annual meeting of stockholders. There are no arrangements or understandings between Ms. Parks and any other person pursuant to which she was selected as a director. In addition, there are no transactions in which Ms. Parks has an interest that would require disclosure under Item 404(a) of Regulation S-K.

Pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"), Ms. Parks (i) will receive an annual cash retainer of $38,000 for service on the Board, and (ii) was granted on the date of her appointment an option to purchase (a) 30,000 shares of the Company's common stock, which vests annually over a three year period, and (b) 8,666 shares of the Company's common stock, which vests in full on the one year anniversary of the date of grant. The Compensation Policy also provides for further automatic annual option grants to purchase 13,000 shares of the Company's common stock on the date of each annual meeting of stockholders, which vest in full on the one year anniversary of the date of grant. Each of the option grants described above will vest in full in the event of a change in control (as defined in the Company's equity incentive plan). Ms. Parks has also entered into the Company's standard form of Indemnification Agreement.

The Company issued a press release announcing the appointment of Ms. Parks, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



               Exhibit
               Number                   Description

               99.1        Press Release dated October 15, 2019.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
08:03aKURA ONCOLOGY, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
08:03aVIRTRA, INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08:03aJOHNSON & JOHNSON : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
08:03aLOCKHEED MARTIN : 's Modernized Turret Adds Performance, Operational Capabilities to the AH-64E Apache Helicopter
PR
08:03aRS2 Focuses on North America, Pursues Single, Global Payment-as-a-Service Platform
BU
08:03aMODO LABS REACHES MILESTONE : 300 Higher Education Customers Use Modo No-Code App Building Platform
BU
08:03aBeeks Financial Cloud Launches New Datacenter with NYI
GL
08:03aCONN ALPH : DermTech's Test Included in Expert Panel's Clinical Management Recommendations for Cutaneous Melanoma
BU
08:03aCOGNITION THERAPEUTICS SPONSORING SATELLITE SYMPOSIUM ON “SIGMA-2 RECEPTORS : Role in Health and Disease” during Society for Neuroscience Annual Meeting
GL
08:03aNYCM INSURANCE : Announces Prestigious Award
BU
Latest news